Literature DB >> 19850700

Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers.

Andreia Biolo1, Mark Fisch, Joshua Balog, Tania Chao, P Christian Schulze, Henry Ooi, Deborah Siwik, Wilson S Colucci.   

Abstract

BACKGROUND: Increased myocyte loss and extracellular matrix (ECM) turnover are central mechanisms that contribute to pathological myocardial remodeling in chronic heart failure (HF). We tested the hypothesis that episodes of acute HF syndrome (AHFS) are associated with transient increases in markers of myocyte injury and ECM turnover beyond those observed in chronic stable HF. METHODS AND
RESULTS: Markers of myocyte injury and ECM turnover were assessed in 80 patients prospectively divided into 3 groups: AHFS (n=39); chronic stable systolic HF (n=21); and control subjects without HF (n=20). Myocyte injury was assessed by measuring plasma troponin I. ECM turnover was assessed by measuring plasma matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, and procollagen N-terminal type I and procollagen type III N-terminal peptides. In the AHFS group, biomarkers were obtained (1) at the time of hospital admission for an episode of HF decompensation, (2) at the time of hospital discharge, and (3) several weeks after discharge in patients who had returned to a chronic stable compensated state. In patients with stable HF (versus non-HF controls), there was a small increase in troponin I and little or no difference in any marker of ECM turnover. In patients with AHFS, troponin I and 3 markers of ECM turnover (matrix metalloproteinases-2, tissue inhibitors of matrix metalloproteinases-1, and procollagen type III N-terminal peptides) were elevated (versus chronic stable HF), and all fell toward chronic HF levels in patients who returned to a compensated state.
CONCLUSIONS: Episodes of AHFS are associated with transient increases in markers of myocyte injury and ECM turnover that may reflect an acceleration of pathological myocardial remodeling during AHFS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850700     DOI: 10.1161/CIRCHEARTFAILURE.108.844324

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  23 in total

1.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation.

Authors:  Marco Metra; Luca Bettari; Franca Pagani; Valentina Lazzarini; Carlo Lombardi; Valentina Carubelli; Graziella Bonetti; Silvia Bugatti; Giovanni Parrinello; Luigi Caimi; G Michael Felker; Livio Dei Cas
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

2.  Congestive heart failure: where homeostasis begets dyshomeostasis.

Authors:  German Kamalov; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

Review 3.  Pathophysiology and clinical evaluation of acute heart failure.

Authors:  Robert J Mentz; Christopher M O'Connor
Journal:  Nat Rev Cardiol       Date:  2015-09-15       Impact factor: 32.419

4.  Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes.

Authors:  Vikas Bhalla; Vasiliki V Georgiopoulou; Ali A Azeem; Catherine N Marti; Robert T Cole; Sonjoy R Laskar; Christine De Staercke; W Craig Hooper; Andrew L Smith; Andreas P Kalogeropoulos; Javed Butler
Journal:  Int J Cardiol       Date:  2011-07-01       Impact factor: 4.164

5.  Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure.

Authors:  Cherinne Arundel; Phillip H Lam; Rahul Khosla; Marc R Blackman; Gregg C Fonarow; Charity Morgan; Qing Zeng; Ross D Fletcher; Javed Butler; Wen-Chih Wu; Prakash Deedwania; Thomas E Love; Michel White; Wilbert S Aronow; Stefan D Anker; Richard M Allman; Ali Ahmed
Journal:  Am J Med       Date:  2016-07-09       Impact factor: 4.965

Review 6.  Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Authors:  Roland E Schmieder; Veselin Mitrovic; Christian Hengstenberg
Journal:  Clin Res Cardiol       Date:  2015-03-19       Impact factor: 5.460

7.  Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling.

Authors:  Tomoko S Kato; Aalap Chokshi; Parvati Singh; Tuba Khawaja; Faisal Cheema; Hirokazu Akashi; Khurram Shahzad; Shinichi Iwata; Shunichi Homma; Hiroo Takayama; Yoshifumi Naka; Ulrich Jorde; Maryjane Farr; Donna M Mancini; P Christian Schulze
Journal:  Circ Heart Fail       Date:  2011-07-15       Impact factor: 8.790

Review 8.  Clinical adoption of prognostic biomarkers: the case for heart failure.

Authors:  Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Javed Butler
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

9.  [Retroperitoneal fibrosis: development of a biomarker profile for diagnosis and therapy monitoring].

Authors:  S Kukuk; A Kretschmer; H Bruck; S Roth; A S Brandt
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

Review 10.  The use of biomarkers in the patient with heart failure.

Authors:  Punam Chowdhury; Devin Kehl; Rajiv Choudhary; Alan Maisel
Journal:  Curr Cardiol Rep       Date:  2013-06       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.